--Oracle, Musk's xAI End Talks on Server Deal, the Information Reports-February 2024-www.financetom.com

--Oracle, Musk's xAI End Talks on Server Deal, the Information Reports

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

--Oracle, Musk's xAI End Talks on Server Deal, the Information Reports

Jul 9, 2024 10:39 AM

01:15 PM EDT, 07/09/2024 (MT Newswires) --

Price: 139.50, Change: -5.53, Percent Change: -3.81

Previous page： Inox Wind & its green energy arm reduce debt by Rs 411 crore Next page： TRAI recommends separate licence for satellite earth station gateway operators

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Inox Wind & its green energy arm reduce debt by Rs 411 crore

Nov 29, 2022

Inox Wind Ltd is India’s leading wind energy solutions provider servicing IPPs, Utilities, PSUs and Corporate investors and Inox Green Energy Services Ltd (IGESL) is one of the leading wind power operations and maintenance (O&M) service providers.

TRAI recommends separate licence for satellite earth station gateway operators

Nov 29, 2022

The Satellite Earth Station Gateway (SESG) permit holders will not provide any service directly to end customers and be levied a non-refundable one-time entry fee of Rs 10 lakh, according to TRAI recommendations.

Biocon Biologics completes acquisition of Viatris' global biosimilars business

Nov 29, 2022

Biocon Biologics and Viatris have obtained all applicable approvals from key global regulators, including the US Federal Trade Commission, the Competition Commission of India and the Reserve Bank of India, and its investors, the Bengaluru-based company said in a statement.

Gland Pharma signs non-binding pact to acquire Europe-based Cenexi for €120 million

Nov 29, 2022

Founded in 2004, Cenexi, along with its subsidiaries, is engaged primarily in the business of contract development and manufacturing organisation (CDMO) of pharmaceutical products with expertise in sterile liquid and lyophilized fill-finished drugs, including capabilities on oncology and complex products.